Retrospective Cohort Study
Copyright ©The Author(s) 2022.
World J Gastroenterol. Apr 21, 2022; 28(15): 1563-1573
Published online Apr 21, 2022. doi: 10.3748/wjg.v28.i15.1563
Table 2 Characteristics of patients with F0-1 fibrosis compared to those with F ≥ 2 fibrosis stage (n = 511)
Variables
Total (n = 511)
Fibrosis stage F0-1 (n = 354)
Fibrosis stage ≥ F2 (n = 157)
P value
Age (yr), median (IQR)51 (41, 58)49.5 (39, 57)55 (48, 61)< 0.001
Sex0.138
Male, n (%)240 (47.0)174 (49.2)66 (42.0)
Female, n (%)271 (53.0)180 (50.8)91 (58.0)
BMI (kg/m2), median (IQR)29.0 (26.3, 32.6)28.8 (26.2, 31.9)29.5 (26.3, 33.8)0.099
Diabetes, n (%)268 (52.4)156 (44.0)112 (71.3)< 0.001
Albumin (g/dL), median (IQR)4.4 (4.1, 4.6)4.4 (4.2, 4.6)4.30 (4.0, 4.6)0.053
Globulin (g/dL), median (IQR)3.4 (3.0, 3.8)3.4 (3.0, 3.8)3.5 (3.1, 3.8)0.21
AST (U/L), median (IQR)39 (28, 60)35 (26, 52)53.5 (36, 75)<0.001
ALT (U/L), median (IQR)65 (42, 101)59.5 (40, 98)75 (50, 111)< 0.001
GGT (U/L), median (IQR)63 (37, 108)56.5 (35, 92)81 (48, 151)< 0.001
Platelet (× 109/μL), median (IQR)254 (213, 297)266 (226.8, 302)230 (189, 277)< 0.001
Hemoglobin (g/dL), median (IQR)14.2 (13.3, 15.2)14.2 (13.4, 15.2)14.1 (13.3, 15.2)0.393
White blood cells (cells/μL), median (IQR)7430 (6060, 8700)7400 (6100, 8725)7500 (5950, 8695)0.768
INR, median (IQR)1.01 (0.96, 1.06)1.00 (0.95, 1.07)1.01 (0.97, 10.6)0.625
Total cholesterol (mg/dL), median (IQR)189.5 (166, 217)193 (170, 220)182 (159, 209)0.004
LDL-cholesterol (mg/dL), median (IQR)115 (92, 139)116 (96, 143)107 (85, 132)0.003
HDL-cholesterol (mg/dL), median (IQR)46 (39, 52)46 (39, 53)44 (38, 50)0.168
Triglyceride (mg/dL), median (IQR)120 (77, 157)120 (77, 155)119 (80, 159)0.483
HbA1C (%), median (IQR)6.1 (5.6, 7.2)5.9 (5.5, 6.8)6.8 (5.8, 7.6)< 0.001
Fibrosis stage, n (%)< 0.001
0151 (29.5)151 (42.7)0 (0)
1203 (39.7)203 (57.3)0 (0)
269 (13.5)0 (0)69 (43.9)
372 (14.1)0 (0)72 (45.9)
416 (3.1)0 (0)16 (10.2)
Median CAP (dB/m), median (IQR)308.5 (230, 342)299 (211, 339)324 (294, 347)< 0.001
Median TE (kPa), median (IQR)7.6 (5.6, 10.9)6.6 (5.1, 8.8)11.1 (8.6, 15.5)< 0.001
FIB-8, median (IQR)2.0 (1.2, 2.9)1.8 (1.1, 2.4)3.0 (2.2, 4.0)< 0.001
FIB-4, median (IQR)1.0 (0.7, 1.5)0.8 (0.6, 1.2)1.5 (1.0, 2.1)< 0.001
NFS, mean ± SD-1.8 ± 1.5-2.0 ± 1.4-1.2 ± 1.3< 0.001
NAFLD: Nonalcoholic fatty liver disease; FIB-8: Fibrosis-8 score; FIB-4: Fibrosis-4 score; NFS: NAFLD fibrosis score; AUROC: Areas under the receiver operating characteristic curves; GGT: Gamma-glutamyl transferase; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; BMI: Body mass index; CAP: Controlled Attenuation Parameter.